OA11076A - Vitronectin receptor antagonists - Google Patents

Vitronectin receptor antagonists Download PDF

Info

Publication number: OA11076A
Authority: OA; OAPI
Prior art keywords: compound; dibenzo; dihydro; cycloheptene; cells
Prior art date: 1997-01-08

Application number

OA9900155A

Other languages

English (en)

Inventor

William H Miller

William E Bondinell

Thomas Wen Fu Ku

Original Assignee

Smithline Beecham Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-01-08

Filing date

1999-07-08

Publication date

2003-03-13

1999-07-08 Application filed by Smithline Beecham Corp filed Critical Smithline Beecham Corp

2003-03-13 Publication of OA11076A publication Critical patent/OA11076A/en

Links

102100022337 Integrin alpha-V Human genes 0.000 title description 17
108010048673 Vitronectin Receptors Proteins 0.000 title description 17
239000002464 receptor antagonist Substances 0.000 title 1
229940044551 receptor antagonist Drugs 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 155
238000000034 method Methods 0.000 claims description 64
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
201000010099 disease Diseases 0.000 claims description 18
239000002246 antineoplastic agent Substances 0.000 claims description 14
206010028980 Neoplasm Diseases 0.000 claims description 13
229940034982 antineoplastic agent Drugs 0.000 claims description 13
230000008569 process Effects 0.000 claims description 10
239000003795 chemical substances by application Substances 0.000 claims description 9
239000008194 pharmaceutical composition Substances 0.000 claims description 9
208000001132 Osteoporosis Diseases 0.000 claims description 7
208000037803 restenosis Diseases 0.000 claims description 7
230000004614 tumor growth Effects 0.000 claims description 7
201000001320 Atherosclerosis Diseases 0.000 claims description 6
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 6
229960004316 cisplatin Drugs 0.000 claims description 6
230000002401 inhibitory effect Effects 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 6
238000007363 ring formation reaction Methods 0.000 claims description 5
206010061218 Inflammation Diseases 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 4
230000004054 inflammatory process Effects 0.000 claims description 4
WYBWIOJIELCLSD-UHFFFAOYSA-N 2-[2-[3-[(4-methylpyridin-2-yl)amino]propoxy]-6,11-dihydro-5h-dibenzo[3,2-[7]annulen-6-yl]acetic acid Chemical compound CC1=CC=NC(NCCCOC=2C=C3CC4=CC=CC=C4C(CC(O)=O)CC3=CC=2)=C1 WYBWIOJIELCLSD-UHFFFAOYSA-N 0.000 claims description 3
UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical group C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 3
229960000303 topotecan Drugs 0.000 claims description 3
XPLUHOMFOBMMAM-UHFFFAOYSA-N 2-[2-[2-[6-(ethylamino)pyridin-2-yl]ethoxy]-6,11-dihydro-5h-dibenzo[3,2-[7]annulen-6-yl]acetic acid Chemical compound CCNC1=CC=CC(CCOC=2C=C3CC4=CC=CC=C4C(CC(O)=O)CC3=CC=2)=N1 XPLUHOMFOBMMAM-UHFFFAOYSA-N 0.000 claims description 2
SOILSVKSKBGUFR-UHFFFAOYSA-N 2-[2-[3-[(4-aminopyridin-2-yl)amino]propoxy]-6,11-dihydro-5h-dibenzo[3,2-[7]annulen-6-yl]acetic acid Chemical compound NC1=CC=NC(NCCCOC=2C=C3CC4=CC=CC=C4C(CC(O)=O)CC3=CC=2)=C1 SOILSVKSKBGUFR-UHFFFAOYSA-N 0.000 claims description 2
206010027476 Metastases Diseases 0.000 claims description 2
230000009401 metastasis Effects 0.000 claims description 2
230000008485 antagonism Effects 0.000 claims 2
230000033115 angiogenesis Effects 0.000 claims 1
229940127449 Integrin Receptor Antagonists Drugs 0.000 abstract 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 77
210000004027 cell Anatomy 0.000 description 60
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 59
239000000243 solution Substances 0.000 description 50
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 43
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 42
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 38
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 37
235000019439 ethyl acetate Nutrition 0.000 description 37
239000000203 mixture Substances 0.000 description 37
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 36
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 34
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 32
210000002997 osteoclast Anatomy 0.000 description 32
229910001868 water Inorganic materials 0.000 description 31
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 29
238000006243 chemical reaction Methods 0.000 description 27
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 24
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 23
239000007787 solid Substances 0.000 description 23
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 22
-1 n-propyl,isopropyl Chemical group 0.000 description 20
229960000583 acetic acid Drugs 0.000 description 18
239000011324 bead Substances 0.000 description 18
238000011282 treatment Methods 0.000 description 18
210000000988 bone and bone Anatomy 0.000 description 17
239000003921 oil Substances 0.000 description 17
235000019198 oils Nutrition 0.000 description 17
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
239000000872 buffer Substances 0.000 description 16
239000002609 medium Substances 0.000 description 15
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 14
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 14
238000003556 assay Methods 0.000 description 14
239000010410 layer Substances 0.000 description 14
235000002639 sodium chloride Nutrition 0.000 description 14
OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 13
238000004809 thin layer chromatography Methods 0.000 description 13
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
229910052786 argon Inorganic materials 0.000 description 12
239000003054 catalyst Substances 0.000 description 12
238000010898 silica gel chromatography Methods 0.000 description 12
239000002904 solvent Substances 0.000 description 12
WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 12
DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 11
230000027455 binding Effects 0.000 description 11
102000005962 receptors Human genes 0.000 description 11
108020003175 receptors Proteins 0.000 description 11
239000000741 silica gel Substances 0.000 description 11
229910002027 silica gel Inorganic materials 0.000 description 11
229960001866 silicon dioxide Drugs 0.000 description 11
239000000725 suspension Substances 0.000 description 11
241000700159 Rattus Species 0.000 description 10
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
239000005557 antagonist Substances 0.000 description 10
238000004587 chromatography analysis Methods 0.000 description 10
239000000706 filtrate Substances 0.000 description 10
230000005764 inhibitory process Effects 0.000 description 10
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
239000012980 RPMI-1640 medium Substances 0.000 description 9
238000001035 drying Methods 0.000 description 9
238000001802 infusion Methods 0.000 description 9
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 8
108010031318 Vitronectin Proteins 0.000 description 8
102100035140 Vitronectin Human genes 0.000 description 8
238000005119 centrifugation Methods 0.000 description 8
HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 8
239000012737 fresh medium Substances 0.000 description 8
229910052763 palladium Inorganic materials 0.000 description 8
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
239000011780 sodium chloride Substances 0.000 description 8
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 7
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 7
241000283690 Bos taurus Species 0.000 description 7
UBQKLVRIDJPLPF-UHFFFAOYSA-N OCCCNC1=CC=CC=[N+]1[O-] Chemical compound OCCCNC1=CC=CC=[N+]1[O-] UBQKLVRIDJPLPF-UHFFFAOYSA-N 0.000 description 7
239000012230 colorless oil Substances 0.000 description 7
239000007788 liquid Substances 0.000 description 7
229910052943 magnesium sulfate Inorganic materials 0.000 description 7
235000019341 magnesium sulphate Nutrition 0.000 description 7
239000000463 material Substances 0.000 description 7
239000011734 sodium Substances 0.000 description 7
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
238000002965 ELISA Methods 0.000 description 6
108010012088 Fibrinogen Receptors Proteins 0.000 description 6
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 6
239000006285 cell suspension Substances 0.000 description 6
238000001914 filtration Methods 0.000 description 6
239000012362 glacial acetic acid Substances 0.000 description 6
238000011534 incubation Methods 0.000 description 6
239000012442 inert solvent Substances 0.000 description 6
YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 6
KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 6
ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 6
229940073584 methylene chloride Drugs 0.000 description 6
210000005087 mononuclear cell Anatomy 0.000 description 6
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 6
238000010992 reflux Methods 0.000 description 6
150000003839 salts Chemical class 0.000 description 6
210000001519 tissue Anatomy 0.000 description 6
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 5
239000006145 Eagle's minimal essential medium Substances 0.000 description 5
208000002966 Giant Cell Tumor of Bone Diseases 0.000 description 5
102000007591 Tartrate-Resistant Acid Phosphatase Human genes 0.000 description 5
108010032050 Tartrate-Resistant Acid Phosphatase Proteins 0.000 description 5
239000002253 acid Substances 0.000 description 5
239000012267 brine Substances 0.000 description 5
239000001110 calcium chloride Substances 0.000 description 5
235000011148 calcium chloride Nutrition 0.000 description 5
229910001628 calcium chloride Inorganic materials 0.000 description 5
230000021164 cell adhesion Effects 0.000 description 5
238000010494 dissociation reaction Methods 0.000 description 5
230000005593 dissociations Effects 0.000 description 5
DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 5
239000003112 inhibitor Substances 0.000 description 5
239000012044 organic layer Substances 0.000 description 5
239000002953 phosphate buffered saline Substances 0.000 description 5
235000017557 sodium bicarbonate Nutrition 0.000 description 5
229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
PORCOIDPPYVUBC-UHFFFAOYSA-N 2-(2-benzyl-4-methoxyphenyl)acetic acid Chemical compound COC1=CC=C(CC(O)=O)C(CC=2C=CC=CC=2)=C1 PORCOIDPPYVUBC-UHFFFAOYSA-N 0.000 description 4
XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 4
102000009027 Albumins Human genes 0.000 description 4
108010088751 Albumins Proteins 0.000 description 4
IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
241001529936 Murinae Species 0.000 description 4
PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
239000012979 RPMI medium Substances 0.000 description 4
235000011054 acetic acid Nutrition 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
239000011575 calcium Substances 0.000 description 4
201000011510 cancer Diseases 0.000 description 4
229910002091 carbon monoxide Inorganic materials 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
239000008121 dextrose Substances 0.000 description 4
208000035475 disorder Diseases 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
239000002502 liposome Substances 0.000 description 4
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
230000009871 nonspecific binding Effects 0.000 description 4
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 4
230000007170 pathology Effects 0.000 description 4
SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
230000003389 potentiating effect Effects 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
239000011541 reaction mixture Substances 0.000 description 4
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
CHADEQDQBURGHL-UHFFFAOYSA-N (6'-acetyloxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl) acetate Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(OC(C)=O)C=C1OC1=CC(OC(=O)C)=CC=C21 CHADEQDQBURGHL-UHFFFAOYSA-N 0.000 description 3
OLTQROWQYPUKHJ-UHFFFAOYSA-N 1-[6-(ethylamino)pyridin-2-yl]ethanol Chemical compound CCNC1=CC=CC(C(C)O)=N1 OLTQROWQYPUKHJ-UHFFFAOYSA-N 0.000 description 3
GRZNODNSNCXOHE-UHFFFAOYSA-N 2-chloro-1-oxidopyridin-1-ium;hydron;chloride Chemical compound Cl.[O-][N+]1=CC=CC=C1Cl GRZNODNSNCXOHE-UHFFFAOYSA-N 0.000 description 3
206010065687 Bone loss Diseases 0.000 description 3
PALINYHTWXGNNL-UHFFFAOYSA-N CC(C)(C)OC(=O)NCCNC1=CC=CC=[N+]1[O-] Chemical compound CC(C)(C)OC(=O)NCCNC1=CC=CC=[N+]1[O-] PALINYHTWXGNNL-UHFFFAOYSA-N 0.000 description 3
241000283707 Capra Species 0.000 description 3
UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 3
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 3
238000005727 Friedel-Crafts reaction Methods 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
229910004003 H5IO6 Inorganic materials 0.000 description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
239000007832 Na2SO4 Substances 0.000 description 3
206010029113 Neovascularisation Diseases 0.000 description 3
101001068640 Nicotiana tabacum Basic form of pathogenesis-related protein 1 Proteins 0.000 description 3
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
150000001336 alkenes Chemical class 0.000 description 3
229940063656 aluminum chloride Drugs 0.000 description 3
230000002491 angiogenic effect Effects 0.000 description 3
150000001540 azides Chemical class 0.000 description 3
239000002585 base Substances 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
210000002805 bone matrix Anatomy 0.000 description 3
244000309466 calf Species 0.000 description 3
VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 3
150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
210000004268 dentin Anatomy 0.000 description 3
FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 3
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
229940093499 ethyl acetate Drugs 0.000 description 3
PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
208000030533 eye disease Diseases 0.000 description 3
238000009472 formulation Methods 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 3
230000012010 growth Effects 0.000 description 3
230000003100 immobilizing effect Effects 0.000 description 3
102000006495 integrins Human genes 0.000 description 3
108010044426 integrins Proteins 0.000 description 3
239000000543 intermediate Substances 0.000 description 3
239000003446 ligand Substances 0.000 description 3
229910001629 magnesium chloride Inorganic materials 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
239000012528 membrane Substances 0.000 description 3
HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 3
JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 3
TWLXDPFBEPBAQB-UHFFFAOYSA-N orthoperiodic acid Chemical compound OI(O)(O)(O)(O)=O TWLXDPFBEPBAQB-UHFFFAOYSA-N 0.000 description 3
238000007248 oxidative elimination reaction Methods 0.000 description 3
239000004033 plastic Substances 0.000 description 3
229920003023 plastic Polymers 0.000 description 3
229910052697 platinum Inorganic materials 0.000 description 3
229920000137 polyphosphoric acid Polymers 0.000 description 3
239000000843 powder Substances 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
230000002335 preservative effect Effects 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
239000013557 residual solvent Substances 0.000 description 3
229960001407 sodium bicarbonate Drugs 0.000 description 3
229910052938 sodium sulfate Inorganic materials 0.000 description 3
235000011152 sodium sulphate Nutrition 0.000 description 3
238000001228 spectrum Methods 0.000 description 3
238000003756 stirring Methods 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
239000006188 syrup Substances 0.000 description 3
235000020357 syrup Nutrition 0.000 description 3
238000012360 testing method Methods 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
231100000331 toxic Toxicity 0.000 description 3
230000002588 toxic effect Effects 0.000 description 3
238000012546 transfer Methods 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
238000005406 washing Methods 0.000 description 3
HYOZJAUAGCFMTK-UHFFFAOYSA-N (2-benzyl-4-methoxyphenyl) trifluoromethanesulfonate Chemical compound COC1=CC=C(OS(=O)(=O)C(F)(F)F)C(CC=2C=CC=CC=2)=C1 HYOZJAUAGCFMTK-UHFFFAOYSA-N 0.000 description 2
KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
CYCBRRHZXAGWOT-UHFFFAOYSA-N 2-benzyl-4-methoxy-1-prop-2-enylbenzene Chemical compound COC1=CC=C(CC=C)C(CC=2C=CC=CC=2)=C1 CYCBRRHZXAGWOT-UHFFFAOYSA-N 0.000 description 2
ZCVHLCUGDIPDLI-UHFFFAOYSA-N 2-benzyl-4-methoxyphenol Chemical compound COC1=CC=C(O)C(CC=2C=CC=CC=2)=C1 ZCVHLCUGDIPDLI-UHFFFAOYSA-N 0.000 description 2
IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
PFLUSECDQBGNLV-UHFFFAOYSA-N 4-ethoxy-3-[3-(3-methoxybenzoyl)phenyl]-4-oxobutanoic acid Chemical compound CCOC(=O)C(CC(O)=O)C1=CC=CC(C(=O)C=2C=C(OC)C=CC=2)=C1 PFLUSECDQBGNLV-UHFFFAOYSA-N 0.000 description 2
BEEPVWPIEFLSNS-UHFFFAOYSA-N 4-ethoxy-3-[3-[(3-methoxyphenyl)methyl]phenyl]-4-oxobutanoic acid Chemical compound CCOC(=O)C(CC(O)=O)C1=CC=CC(CC=2C=C(OC)C=CC=2)=C1 BEEPVWPIEFLSNS-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
208000010392 Bone Fractures Diseases 0.000 description 2
KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
AKFFEOGDSYZFBT-UHFFFAOYSA-N CC1=CC=[N+]([O-])C(NCCCO)=C1 Chemical compound CC1=CC=[N+]([O-])C(NCCCO)=C1 AKFFEOGDSYZFBT-UHFFFAOYSA-N 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
108010022452 Collagen Type I Proteins 0.000 description 2
102000012422 Collagen Type I Human genes 0.000 description 2
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 2
KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
206010020584 Hypercalcaemia of malignancy Diseases 0.000 description 2
201000002980 Hyperparathyroidism Diseases 0.000 description 2
239000003810 Jones reagent Substances 0.000 description 2
240000007472 Leucaena leucocephala Species 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
229910021380 Manganese Chloride Inorganic materials 0.000 description 2
GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 2
FBVSUCGIZRGLIU-UHFFFAOYSA-N OCCCNC1=CC([N+]([O-])=O)=CC=[N+]1[O-] Chemical compound OCCCNC1=CC([N+]([O-])=O)=CC=[N+]1[O-] FBVSUCGIZRGLIU-UHFFFAOYSA-N 0.000 description 2
208000010191 Osteitis Deformans Diseases 0.000 description 2
108010081689 Osteopontin Proteins 0.000 description 2
102000004264 Osteopontin Human genes 0.000 description 2
208000027868 Paget disease Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
101000781681 Protobothrops flavoviridis Disintegrin triflavin Proteins 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
206010052428 Wound Diseases 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
239000000654 additive Substances 0.000 description 2
102000019997 adhesion receptor Human genes 0.000 description 2
108010013985 adhesion receptor Proteins 0.000 description 2
125000001931 aliphatic group Chemical group 0.000 description 2
YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 2
230000036770 blood supply Effects 0.000 description 2
210000004204 blood vessel Anatomy 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000000969 carrier Substances 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
239000012320 chlorinating reagent Substances 0.000 description 2
238000004440 column chromatography Methods 0.000 description 2
238000004624 confocal microscopy Methods 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
230000007812 deficiency Effects 0.000 description 2
239000008367 deionised water Substances 0.000 description 2
229910021641 deionized water Inorganic materials 0.000 description 2
230000002939 deleterious effect Effects 0.000 description 2
238000000502 dialysis Methods 0.000 description 2
PJQCANLCUDUPRF-UHFFFAOYSA-N dibenzocycloheptene Chemical compound C1CC2=CC=CC=C2CC2=CC=CC=C12 PJQCANLCUDUPRF-UHFFFAOYSA-N 0.000 description 2
YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
XRQIGNDXQJCXOW-UHFFFAOYSA-N ethyl 2-(2-hydroxy-6,11-dihydro-5h-dibenzo[3,2-[7]annulen-6-yl)acetate Chemical compound CCOC(=O)CC1CC2=CC=C(O)C=C2CC2=CC=CC=C12 XRQIGNDXQJCXOW-UHFFFAOYSA-N 0.000 description 2
HQKBUYHLEORNIT-UHFFFAOYSA-N ethyl 2-[3-(3-methoxyphenyl)-1h-inden-1-yl]acetate Chemical compound C12=CC=CC=C2C(CC(=O)OCC)C=C1C1=CC=CC(OC)=C1 HQKBUYHLEORNIT-UHFFFAOYSA-N 0.000 description 2
ZBWSMCJLJRHNHT-UHFFFAOYSA-N ethyl 2-[6-(ethylamino)pyridin-2-yl]acetate Chemical compound CCNC1=CC=CC(CC(=O)OCC)=N1 ZBWSMCJLJRHNHT-UHFFFAOYSA-N 0.000 description 2
OOOUWLXKQSGGEZ-UHFFFAOYSA-N ethyl 2-[6-[ethyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]pyridin-2-yl]acetate Chemical compound CCOC(=O)CC1=CC=CC(N(CC)C(=O)OC(C)(C)C)=N1 OOOUWLXKQSGGEZ-UHFFFAOYSA-N 0.000 description 2
FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 2
238000000605 extraction Methods 0.000 description 2
235000019253 formic acid Nutrition 0.000 description 2
239000012634 fragment Substances 0.000 description 2
239000011521 glass Substances 0.000 description 2
239000003163 gonadal steroid hormone Substances 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
210000005119 human aortic smooth muscle cell Anatomy 0.000 description 2
208000008750 humoral hypercalcemia of malignancy Diseases 0.000 description 2
239000005457 ice water Substances 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
239000002198 insoluble material Substances 0.000 description 2
239000012669 liquid formulation Substances 0.000 description 2
238000005567 liquid scintillation counting Methods 0.000 description 2
208000027202 mammary Paget disease Diseases 0.000 description 2
239000011565 manganese chloride Substances 0.000 description 2
235000002867 manganese chloride Nutrition 0.000 description 2
239000003550 marker Substances 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
238000000386 microscopy Methods 0.000 description 2
230000005012 migration Effects 0.000 description 2
238000013508 migration Methods 0.000 description 2
238000003801 milling Methods 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
229910000489 osmium tetroxide Inorganic materials 0.000 description 2
230000011164 ossification Effects 0.000 description 2
230000000010 osteolytic effect Effects 0.000 description 2
239000007800 oxidant agent Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
239000012071 phase Substances 0.000 description 2
210000002826 placenta Anatomy 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229940002612 prodrug Drugs 0.000 description 2
239000000651 prodrug Substances 0.000 description 2
238000000159 protein binding assay Methods 0.000 description 2
238000000746 purification Methods 0.000 description 2
LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
239000002287 radioligand Substances 0.000 description 2
WOCIAKWEIIZHES-UHFFFAOYSA-N ruthenium(iv) oxide Chemical compound O=[Ru]=O WOCIAKWEIIZHES-UHFFFAOYSA-N 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
238000012216 screening Methods 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
XSVAARVWQDEAEL-UHFFFAOYSA-N tert-butyl n-(6-methylpyridin-2-yl)carbamate Chemical compound CC1=CC=CC(NC(=O)OC(C)(C)C)=N1 XSVAARVWQDEAEL-UHFFFAOYSA-N 0.000 description 2
LNGSPBARAFUWCQ-UHFFFAOYSA-N tert-butyl n-[2-(pyridin-2-ylamino)ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCNC1=CC=CC=N1 LNGSPBARAFUWCQ-UHFFFAOYSA-N 0.000 description 2
UFHQRJBMMVDTOC-UHFFFAOYSA-N tert-butyl n-ethyl-n-(6-methylpyridin-2-yl)carbamate Chemical compound CC(C)(C)OC(=O)N(CC)C1=CC=CC(C)=N1 UFHQRJBMMVDTOC-UHFFFAOYSA-N 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
230000003442 weekly effect Effects 0.000 description 2
239000008096 xylene Substances 0.000 description 2
150000003738 xylenes Chemical class 0.000 description 2
HZSBSRAVNBUZRA-RQDPQJJXSA-J (1r,2r)-cyclohexane-1,2-diamine;tetrachloroplatinum(2+) Chemical compound Cl[Pt+2](Cl)(Cl)Cl.N[C@@H]1CCCC[C@H]1N HZSBSRAVNBUZRA-RQDPQJJXSA-J 0.000 description 1
UHEPSJJJMTWUCP-DHDYTCSHSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-[(1r)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;sulfuric acid Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N UHEPSJJJMTWUCP-DHDYTCSHSA-N 0.000 description 1
CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical compound C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 description 1
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
XLBBKEHLEPNMMF-SSUNCQRMSA-N 129038-42-2 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)[C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCC(O)=O)C1=CC=CC=C1 XLBBKEHLEPNMMF-SSUNCQRMSA-N 0.000 description 1
XFEFRJSZJKFVKG-UHFFFAOYSA-N 2-(2-benzoyl-4-methoxyphenyl)acetic acid Chemical compound COC1=CC=C(CC(O)=O)C(C(=O)C=2C=CC=CC=2)=C1 XFEFRJSZJKFVKG-UHFFFAOYSA-N 0.000 description 1
BJLRCBHYSXQPEV-UHFFFAOYSA-N 2-(2-benzyl-5-methoxyphenyl)acetic acid Chemical compound OC(=O)CC1=CC(OC)=CC=C1CC1=CC=CC=C1 BJLRCBHYSXQPEV-UHFFFAOYSA-N 0.000 description 1
KNNHPOGBBNRNDH-UHFFFAOYSA-N 2-[(2-chloro-6-fluorophenyl)methylsulfanyl]ethanamine Chemical compound NCCSCC1=C(F)C=CC=C1Cl KNNHPOGBBNRNDH-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
WYSRTEVFLQJJDN-UHFFFAOYSA-N 2-chloro-1-oxidopyridin-1-ium Chemical compound [O-][N+]1=CC=CC=C1Cl WYSRTEVFLQJJDN-UHFFFAOYSA-N 0.000 description 1
CTRINZIZOOSLLD-UHFFFAOYSA-N 2-chloro-4-methyl-1-oxidopyridin-1-ium Chemical group CC1=CC=[N+]([O-])C(Cl)=C1 CTRINZIZOOSLLD-UHFFFAOYSA-N 0.000 description 1
YSTCMHHKDOVZDA-UHFFFAOYSA-N 2-chloro-4-nitro-1-oxidopyridin-1-ium Chemical group [O-][N+](=O)C1=CC=[N+]([O-])C(Cl)=C1 YSTCMHHKDOVZDA-UHFFFAOYSA-N 0.000 description 1
YTWCDMNIQZKXFH-UHFFFAOYSA-N 2-methoxy-5,11-dihydrodibenzo[2,3-e:2',1'-f][7]annulen-6-one Chemical compound C1C(=O)C2=CC=CC=C2CC2=CC(OC)=CC=C21 YTWCDMNIQZKXFH-UHFFFAOYSA-N 0.000 description 1
NTSRMGPINJLVFK-UHFFFAOYSA-N 3-(3-methoxyphenyl)-1h-indene Chemical compound COC1=CC=CC(C=2C3=CC=CC=C3CC=2)=C1 NTSRMGPINJLVFK-UHFFFAOYSA-N 0.000 description 1
MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
229960000549 4-dimethylaminophenol Drugs 0.000 description 1
HJUUXXYBCIQSOR-UHFFFAOYSA-N 6-(2-ethoxy-2-oxoethyl)-11h-dibenzo[3,1-e:2',1'-f][7]annulene-3-carboxylic acid Chemical compound CCOC(=O)CC1=CC2=CC(C(O)=O)=CC=C2CC2=CC=CC=C12 HJUUXXYBCIQSOR-UHFFFAOYSA-N 0.000 description 1
QUXLCYFNVNNRBE-UHFFFAOYSA-N 6-methylpyridin-2-amine Chemical compound CC1=CC=CC(N)=N1 QUXLCYFNVNNRBE-UHFFFAOYSA-N 0.000 description 1
NALREUIWICQLPS-UHFFFAOYSA-N 7-imino-n,n-dimethylphenothiazin-3-amine;hydrochloride Chemical compound [Cl-].C1=C(N)C=C2SC3=CC(=[N+](C)C)C=CC3=NC2=C1 NALREUIWICQLPS-UHFFFAOYSA-N 0.000 description 1
FUXVKZWTXQUGMW-FQEVSTJZSA-N 9-Aminocamptothecin Chemical compound C1=CC(N)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 FUXVKZWTXQUGMW-FQEVSTJZSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
102000013563 Acid Phosphatase Human genes 0.000 description 1
108010051457 Acid Phosphatase Proteins 0.000 description 1
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
208000027496 Behcet disease Diseases 0.000 description 1
229940122361 Bisphosphonate Drugs 0.000 description 1
MMAIWPFHDSTILW-UHFFFAOYSA-N CC(C)(C)OC(=O)C1=CC2=C(CC3=CC=CC=C3C(=C2)CC(=O)O)C=C1 Chemical compound CC(C)(C)OC(=O)C1=CC2=C(CC3=CC=CC=C3C(=C2)CC(=O)O)C=C1 MMAIWPFHDSTILW-UHFFFAOYSA-N 0.000 description 1
101150041968 CDC13 gene Proteins 0.000 description 1
102000055006 Calcitonin Human genes 0.000 description 1
108060001064 Calcitonin Proteins 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
241000252095 Congridae Species 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
206010012442 Dermatitis contact Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
206010012689 Diabetic retinopathy Diseases 0.000 description 1
OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 1
LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
101000761020 Dinoponera quadriceps Poneritoxin Proteins 0.000 description 1
208000005189 Embolism Diseases 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
206010063560 Excessive granulation tissue Diseases 0.000 description 1
108010073385 Fibrin Proteins 0.000 description 1
102000009123 Fibrin Human genes 0.000 description 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
108010067306 Fibronectins Proteins 0.000 description 1
102000016359 Fibronectins Human genes 0.000 description 1
238000001157 Fourier transform infrared spectrum Methods 0.000 description 1
206010017076 Fracture Diseases 0.000 description 1
208000010412 Glaucoma Diseases 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
208000009329 Graft vs Host Disease Diseases 0.000 description 1
108060003393 Granulin Proteins 0.000 description 1
229910004373 HOAc Inorganic materials 0.000 description 1
208000005100 Herpetic Keratitis Diseases 0.000 description 1
201000002563 Histoplasmosis Diseases 0.000 description 1
101000613820 Homo sapiens Osteopontin Proteins 0.000 description 1
101000703512 Homo sapiens Sphingosine-1-phosphate phosphatase 1 Proteins 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
102000007547 Laminin Human genes 0.000 description 1
108010085895 Laminin Proteins 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
LOJFGJZQOKTUBR-XAQOOIOESA-N NC(N)=NCCC[C@@H](C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(O)=O)C)CC1=CN=CN1 Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(O)=O)C)CC1=CN=CN1 LOJFGJZQOKTUBR-XAQOOIOESA-N 0.000 description 1
208000034827 Neointima Diseases 0.000 description 1
241001122605 Novosphingobium indicum Species 0.000 description 1
206010073938 Ophthalmic herpes simplex Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
102000004067 Osteocalcin Human genes 0.000 description 1
108090000573 Osteocalcin Proteins 0.000 description 1
241001111421 Pannus Species 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
108010039918 Polylysine Proteins 0.000 description 1
WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
201000002154 Pterygium Diseases 0.000 description 1
101001121466 Rattus norvegicus Osteopontin Proteins 0.000 description 1
101000703459 Rattus norvegicus Sphingosine-1-phosphate phosphatase 1 Proteins 0.000 description 1
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
208000017442 Retinal disease Diseases 0.000 description 1
206010038923 Retinopathy Diseases 0.000 description 1
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
108010032838 Sialoglycoproteins Proteins 0.000 description 1
102000007365 Sialoglycoproteins Human genes 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
108060008245 Thrombospondin Proteins 0.000 description 1
102000002938 Thrombospondin Human genes 0.000 description 1
229910021627 Tin(IV) chloride Inorganic materials 0.000 description 1
102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
HUXIAXQSTATULQ-UHFFFAOYSA-N [6-bromo-3-[(2-methoxyphenyl)carbamoyl]naphthalen-2-yl] dihydrogen phosphate Chemical compound COC1=CC=CC=C1NC(=O)C1=CC2=CC(Br)=CC=C2C=C1OP(O)(O)=O HUXIAXQSTATULQ-UHFFFAOYSA-N 0.000 description 1
SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
239000008351 acetate buffer Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
238000005575 aldol reaction Methods 0.000 description 1
150000004703 alkoxides Chemical class 0.000 description 1
230000007815 allergy Effects 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
WLDHEUZGFKACJH-UHFFFAOYSA-K amaranth Chemical compound [Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=C1N=NC1=CC=C(S([O-])(=O)=O)C2=CC=CC=C12 WLDHEUZGFKACJH-UHFFFAOYSA-K 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000004037 angiogenesis inhibitor Substances 0.000 description 1
230000001772 anti-angiogenic effect Effects 0.000 description 1
229940046836 anti-estrogen Drugs 0.000 description 1
230000001833 anti-estrogenic effect Effects 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
239000002257 antimetastatic agent Substances 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
239000000010 aprotic solvent Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
239000012148 binding buffer Substances 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
XGIUDIMNNMKGDE-UHFFFAOYSA-N bis(trimethylsilyl)azanide Chemical compound C[Si](C)(C)[N-][Si](C)(C)C XGIUDIMNNMKGDE-UHFFFAOYSA-N 0.000 description 1
150000004663 bisphosphonates Chemical class 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
230000036765 blood level Effects 0.000 description 1
238000010241 blood sampling Methods 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000011449 brick Substances 0.000 description 1
KDPAWGWELVVRCH-UHFFFAOYSA-M bromoacetate Chemical compound [O-]C(=O)CBr KDPAWGWELVVRCH-UHFFFAOYSA-M 0.000 description 1
229940045348 brown mixture Drugs 0.000 description 1
230000005587 bubbling Effects 0.000 description 1
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
229960004015 calcitonin Drugs 0.000 description 1
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001721 carbon Chemical class 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
230000012292 cell migration Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
238000010367 cloning Methods 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
108010049937 collagen type I trimeric cross-linked peptide Proteins 0.000 description 1
229940125904 compound 1 Drugs 0.000 description 1
208000010247 contact dermatitis Diseases 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
150000004696 coordination complex Chemical class 0.000 description 1
238000007887 coronary angioplasty Methods 0.000 description 1
230000001054 cortical effect Effects 0.000 description 1
230000008878 coupling Effects 0.000 description 1
239000012043 crude product Substances 0.000 description 1
150000003997 cyclic ketones Chemical class 0.000 description 1
UVJHQYIOXKWHFD-UHFFFAOYSA-N cyclohexa-1,4-diene Chemical compound C1C=CCC=C1 UVJHQYIOXKWHFD-UHFFFAOYSA-N 0.000 description 1
150000008508 dibenzocycloheptenes Chemical group 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
108010025752 echistatin Proteins 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
238000000921 elemental analysis Methods 0.000 description 1
239000000328 estrogen antagonist Substances 0.000 description 1
MZQDZKKLPJELBN-UHFFFAOYSA-N ethyl 2-(2-methoxy-5-oxo-6,11-dihydrodibenzo[1,2-b:3',1'-e][7]annulen-6-yl)acetate Chemical compound O=C1C(CC(=O)OCC)C2=CC=CC=C2CC2=CC(OC)=CC=C21 MZQDZKKLPJELBN-UHFFFAOYSA-N 0.000 description 1
YNERNFDGTRKOGO-UHFFFAOYSA-N ethyl 2-(6-hydroxy-2-methoxy-5,11-dihydrodibenzo[1,2-b:2',3'-f][7]annulen-6-yl)acetate Chemical compound CCOC(=O)CC1(O)CC2=CC=C(OC)C=C2CC2=CC=CC=C12 YNERNFDGTRKOGO-UHFFFAOYSA-N 0.000 description 1
VZZILYIHWKSTRY-UHFFFAOYSA-N ethyl 2-[2-[3-[(4-aminopyridin-2-yl)amino]propoxy]-6,11-dihydro-5h-dibenzo[3,2-[7]annulen-6-yl]acetate Chemical compound C1=C2CC3=CC=CC=C3C(CC(=O)OCC)CC2=CC=C1OCCCNC1=CC(N)=CC=N1 VZZILYIHWKSTRY-UHFFFAOYSA-N 0.000 description 1
125000004494 ethyl ester group Chemical group 0.000 description 1
201000010934 exostosis Diseases 0.000 description 1
238000010265 fast atom bombardment Methods 0.000 description 1
229950003499 fibrin Drugs 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
238000011049 filling Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
238000005227 gel permeation chromatography Methods 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
238000007429 general method Methods 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
108010045624 glutamyl-lysyl-alanyl-histidyl-aspartyl-glycyl-glycyl-arginine Proteins 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
229940074045 glyceryl distearate Drugs 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
208000024908 graft versus host disease Diseases 0.000 description 1
210000001126 granulation tissue Anatomy 0.000 description 1
230000005484 gravity Effects 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000035876 healing Effects 0.000 description 1
230000002439 hemostatic effect Effects 0.000 description 1
201000010884 herpes simplex virus keratitis Diseases 0.000 description 1
GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
239000012456 homogeneous solution Substances 0.000 description 1
238000002657 hormone replacement therapy Methods 0.000 description 1
150000002431 hydrogen Chemical class 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
238000007327 hydrogenolysis reaction Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
201000010930 hyperostosis Diseases 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
238000002329 infrared spectrum Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
229960004768 irinotecan Drugs 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
206010023332 keratitis Diseases 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
239000008101 lactose Substances 0.000 description 1
108010034897 lentil lectin Proteins 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
239000006166 lysate Substances 0.000 description 1
208000002780 macular degeneration Diseases 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
229940071648 metered dose inhaler Drugs 0.000 description 1
ULUNVGXIIRTCRA-UHFFFAOYSA-N methyl 2-(2-benzoyl-5-methoxyphenyl)acetate Chemical compound COC(=O)CC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 ULUNVGXIIRTCRA-UHFFFAOYSA-N 0.000 description 1
NGBCQTSPVYBIAJ-UHFFFAOYSA-N methyl 2-(2-benzyl-5-methoxyphenyl)acetate Chemical compound COC(=O)CC1=CC(OC)=CC=C1CC1=CC=CC=C1 NGBCQTSPVYBIAJ-UHFFFAOYSA-N 0.000 description 1
238000010232 migration assay Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
230000000921 morphogenic effect Effects 0.000 description 1
YJGUUWHSAANPMU-UHFFFAOYSA-N n'-pyridin-2-ylethane-1,2-diamine;dihydrochloride Chemical compound Cl.Cl.NCCNC1=CC=CC=N1 YJGUUWHSAANPMU-UHFFFAOYSA-N 0.000 description 1
PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
201000003142 neovascular glaucoma Diseases 0.000 description 1
230000037311 normal skin Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
229950008017 ormaplatin Drugs 0.000 description 1
239000012285 osmium tetroxide Substances 0.000 description 1
230000001599 osteoclastic effect Effects 0.000 description 1
208000005368 osteomalacia Diseases 0.000 description 1
208000002865 osteopetrosis Diseases 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000020477 pH reduction Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000001814 pectin Substances 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
229940063179 platinol Drugs 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
229920000656 polylysine Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000013641 positive control Substances 0.000 description 1
235000011056 potassium acetate Nutrition 0.000 description 1
WFIZEGIEIOHZCP-UHFFFAOYSA-M potassium formate Chemical compound [K+].[O-]C=O WFIZEGIEIOHZCP-UHFFFAOYSA-M 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
239000000047 product Substances 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
238000011552 rat model Methods 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000007634 remodeling Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
238000013391 scatchard analysis Methods 0.000 description 1
230000036303 septic shock Effects 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
230000015590 smooth muscle cell migration Effects 0.000 description 1
239000003998 snake venom Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
229960001790 sodium citrate Drugs 0.000 description 1
235000011083 sodium citrates Nutrition 0.000 description 1
IHQKEDIOMGYHEB-UHFFFAOYSA-M sodium dimethylarsinate Chemical compound [Na+].C[As](C)([O-])=O IHQKEDIOMGYHEB-UHFFFAOYSA-M 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 1
239000001433 sodium tartrate Substances 0.000 description 1
229960002167 sodium tartrate Drugs 0.000 description 1
235000011004 sodium tartrates Nutrition 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
230000007480 spreading Effects 0.000 description 1
230000010473 stable expression Effects 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
239000012258 stirred mixture Substances 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000000454 talc Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 description 1
BXVLZVTWCPCGHV-UHFFFAOYSA-N tert-butyl 6-oxo-5,11-dihydrodibenzo[3,2-e:2',1'-f][7]annulene-3-carboxylate Chemical compound O=C1CC2=CC(C(=O)OC(C)(C)C)=CC=C2CC2=CC=CC=C21 BXVLZVTWCPCGHV-UHFFFAOYSA-N 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
229940034208 thyroxine Drugs 0.000 description 1
XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
229950003937 tolonium Drugs 0.000 description 1
HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
238000001890 transfection Methods 0.000 description 1
108091007466 transmembrane glycoproteins Proteins 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
YLGRTLMDMVAFNI-UHFFFAOYSA-N tributyl(prop-2-enyl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)CC=C YLGRTLMDMVAFNI-UHFFFAOYSA-N 0.000 description 1
238000001665 trituration Methods 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
229960001134 von willebrand factor Drugs 0.000 description 1
238000010626 work up procedure Methods 0.000 description 1
230000029663 wound healing Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/734—Ethers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Rheumatology (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

OA9900155A 1997-01-08 1999-07-08 Vitronectin receptor antagonists OA11076A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US3402697P	1997-01-08	1997-01-08

Publications (1)

Publication Number	Publication Date
OA11076A true OA11076A (en)	2003-03-13

Family

ID=21873846

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA9900155A OA11076A (en)	1997-01-08	1999-07-08	Vitronectin receptor antagonists

Country Status (30)

Country	Link
US (2)	US6069158A (es)
EP (1)	EP0977735B1 (es)
JP (1)	JP2001508067A (es)
KR (1)	KR20000069941A (es)
CN (1)	CN1249745A (es)
AP (1)	AP9901597A0 (es)
AR (1)	AR010873A1 (es)
AT (1)	ATE235467T1 (es)
AU (1)	AU729641B2 (es)
BG (1)	BG103548A (es)
BR (1)	BR9806852A (es)
CA (1)	CA2276738A1 (es)
CO (1)	CO4920232A1 (es)
DE (1)	DE69812602T2 (es)
DZ (1)	DZ2395A1 (es)
EA (1)	EA199900630A1 (es)
ES (1)	ES2196534T3 (es)
HU (1)	HUP0001945A3 (es)
ID (1)	ID23168A (es)
IL (1)	IL130760A0 (es)
MA (1)	MA26462A1 (es)
NO (1)	NO993350L (es)
NZ (1)	NZ336560A (es)
OA (1)	OA11076A (es)
PE (1)	PE44799A1 (es)
PL (1)	PL334499A1 (es)
SK (1)	SK92799A3 (es)
TR (1)	TR199901575T2 (es)
WO (1)	WO1998030542A1 (es)
ZA (1)	ZA9896B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2304117A1 (en) *	1997-09-04	1999-03-11	Dirk A. Heerding	Integrin receptor antagonists
US6576643B2 (en)	1997-09-19	2003-06-10	Smithkline Beecham Corporation	Vitronectin receptor antagonists
PE122699A1 (es) *	1997-09-19	2000-02-12	Smithkline Beecham Corp	Antagonistas de receptores de vitronectina
CA2327673C (en)	1998-04-09	2009-08-25	Meiji Seika Kaisha, Ltd.	Aminopiperidine derivatives as integrin .alpha.v.beta.3 antagonists
JP4240424B2 (ja) *	1998-10-23	2009-03-18	エルジーディスプレイカンパニーリミテッド	エッチング剤及びこれを用いた電子機器用基板の製造方法
US6339083B1 (en)	1998-12-14	2002-01-15	Bayer Aktiengesellschaft	Multiheterocyclic pharmAceuticals
WO2000046215A1 (en)	1999-02-03	2000-08-10	Merck & Co., Inc.	Benzazepine derivatives as alpha-v integrin receptor antagonists
DE19916837A1 (de) *	1999-04-14	2000-10-19	Merck Patent Gmbh	Dibenzoazulenderivate
WO2001010844A1 (fr)	1999-08-05	2001-02-15	Meiji Seika Kaisha, Ltd.	DERIVES D'ACIDE φ-AMINO-α-HYDROXYCARBOXYLIQUE POSSEDANT UN ANTAGONISME αvβ3 D'INTEGRINE
DE19936780A1 (de)	1999-08-09	2001-02-15	Basf Ag	Neue Antagonisten von Integrinrezeptoren
FR2806082B1 (fr) *	2000-03-07	2002-05-17	Adir	Nouveaux composes bicycliques antagonistes des recepteurs de la vitronectine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU3943502A (en) *	2000-10-24	2002-05-27	Merck & Co Inc	Dibenzoxazepine alpha v integrin receptor antagonist
WO2002085405A2 (en)	2001-04-24	2002-10-31	Merck Patent Gmbh	COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNF$g(a)
JP4750360B2 (ja)	2001-10-22	2011-08-17	ザスクリプスリサーチインスティチュート	抗体ターゲッティング化合物
GB0215867D0 (en) *	2002-07-09	2002-08-14	Glaxosmithkline Spa	Novel method and compounds
AU2012216372B2 (en) *	2004-04-02	2015-01-22	The Regents Of The University Of California	Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin
CN1964740A (zh) *	2004-04-02	2007-05-16	加利福尼亚大学董事会	治疗和预防与αVβ5整联蛋白有关的疾病的方法和组合物
UA87854C2 (en)	2004-06-07	2009-08-25	Мерк Энд Ко., Инк.	N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
US8282943B2 (en)	2005-05-31	2012-10-09	Ralf Jochem	Therapeutic composition for use in the prevention and treatment of bone metastases
EP1945262A2 (en) *	2005-10-20	2008-07-23	The Scripps Research Institute	Fc labeling for immunostaining and immunotargeting
ES2521679T3 (es)	2006-01-18	2014-11-13	Merck Patent Gmbh	Terapia específica usando ligandos de integrinas para el tratamiento del cáncer
US20100069302A1 (en)	2007-07-18	2010-03-18	Stefan Krueger	Specific therapy and medicament using integrin ligands for treating cancer
BRPI0821090B8 (pt)	2007-12-21	2021-05-25	Ligand Pharm Inc	moduladores seletivos de receptores de androgênio (sarms) e uso do mesmo
US8518927B2 (en)	2009-02-10	2013-08-27	The Scripps Research Institute	Chemically programmed vaccination
CN102448497A (zh)	2009-05-25	2012-05-09	默克专利有限公司	在癌症治疗中的西仑吉肽的持续给药
JP5755647B2 (ja)	2009-07-24	2015-07-29	ザリージェンツオブザユニバーシティオブカリフォルニア	αｖβ５インテグリンに関連する疾患の処置および予防のための方法および組成物
CA2950390C (en)	2014-05-30	2020-09-22	Pfizer Inc.	Carbonitrile derivatives as selective androgen receptor modulators
EP3956309A4 (en)	2019-04-19	2023-06-07	Ligand Pharmaceuticals Inc.	CRYSTALLINE FORMS AND METHODS FOR PRODUCING CRYSTALLINE FORMS OF A COMPOUND
WO2023275715A1 (en)	2021-06-30	2023-01-05	Pfizer Inc.	Metabolites of selective androgen receptor modulators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE794424A (fr) *	1972-01-24	1973-07-23	Science Union & Cie	Nouveaux dibenzocycloheptenes, leur procede d'obtention et leur application comme medicament
US3906032A (en) *	1972-11-10	1975-09-16	Squibb & Sons Inc	Dihydroxy-tetrahydronaphthyoxyisobutyric acids and alkyl esters and salts thereof
IT1222986B (it) *	1987-10-23	1990-09-12	Texcontor Ets	Derivati dell'efedrina esterificata aventi attivita' antiulcera prolungata nel tempo
US4994463A (en) *	1987-12-14	1991-02-19	Kyowa Hakko Kogyo Co., Ltd.	Tricyclic thromboxane A2 antagonists
PT910563E (pt) *	1995-06-29	2003-09-30	Smithkline Beecham Corp	Antagonistas de receptores de integrina
WO1997024124A1 (en) *	1995-12-29	1997-07-10	Smithkline Beecham Corporation	Vitronectin receptor antagonists
WO1999005107A1 (en) *	1997-07-25	1999-02-04	Smithkline Beecham Corporation	Vitronectin receptor antagonist
PE122699A1 (es) *	1997-09-19	2000-02-12	Smithkline Beecham Corp	Antagonistas de receptores de vitronectina

1997
- 1997-12-30 CO CO97075531A patent/CO4920232A1/es unknown
1998
- 1998-01-02 MA MA24917A patent/MA26462A1/fr unknown
- 1998-01-05 AR ARP980100031A patent/AR010873A1/es not_active Application Discontinuation
- 1998-01-07 PE PE1998000013A patent/PE44799A1/es not_active Application Discontinuation
- 1998-01-07 ZA ZA9896A patent/ZA9896B/xx unknown
- 1998-01-08 AP APAP/P/1999/001597A patent/AP9901597A0/en unknown
- 1998-01-08 BR BR9806852-0A patent/BR9806852A/pt not_active Application Discontinuation
- 1998-01-08 NZ NZ336560A patent/NZ336560A/xx unknown
- 1998-01-08 WO PCT/US1998/000490 patent/WO1998030542A1/en not_active Ceased
- 1998-01-08 SK SK927-99A patent/SK92799A3/sk unknown
- 1998-01-08 US US09/331,914 patent/US6069158A/en not_active Expired - Lifetime
- 1998-01-08 CN CN98802983A patent/CN1249745A/zh active Pending
- 1998-01-08 ID IDW990650D patent/ID23168A/id unknown
- 1998-01-08 HU HU0001945A patent/HUP0001945A3/hu unknown
- 1998-01-08 EA EA199900630A patent/EA199900630A1/ru unknown
- 1998-01-08 EP EP98902477A patent/EP0977735B1/en not_active Expired - Lifetime
- 1998-01-08 KR KR1019997006154A patent/KR20000069941A/ko not_active Ceased
- 1998-01-08 PL PL98334499A patent/PL334499A1/xx unknown
- 1998-01-08 JP JP53117598A patent/JP2001508067A/ja active Pending
- 1998-01-08 AT AT98902477T patent/ATE235467T1/de not_active IP Right Cessation
- 1998-01-08 DE DE69812602T patent/DE69812602T2/de not_active Expired - Lifetime
- 1998-01-08 CA CA002276738A patent/CA2276738A1/en not_active Abandoned
- 1998-01-08 TR TR1999/01575T patent/TR199901575T2/xx unknown
- 1998-01-08 ES ES98902477T patent/ES2196534T3/es not_active Expired - Lifetime
- 1998-01-08 AU AU59127/98A patent/AU729641B2/en not_active Ceased
- 1998-01-08 IL IL13076098A patent/IL130760A0/xx unknown
- 1998-06-07 DZ DZ980005A patent/DZ2395A1/xx active
1999
- 1999-07-01 BG BG103548A patent/BG103548A/xx unknown
- 1999-07-07 NO NO993350A patent/NO993350L/no not_active Application Discontinuation
- 1999-07-08 OA OA9900155A patent/OA11076A/en unknown
2000
- 2000-04-18 US US09/551,743 patent/US6191304B1/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
AP9901597A0 (en)	1999-09-30
HUP0001945A2 (hu)	2000-10-28
CA2276738A1 (en)	1998-07-16
US6191304B1 (en)	2001-02-20
DE69812602D1 (de)	2003-04-30
BR9806852A (pt)	2001-08-07
EP0977735B1 (en)	2003-03-26
NO993350D0 (no)	1999-07-07
HUP0001945A3 (en)	2001-12-28
EP0977735A4 (en)	2000-04-05
ATE235467T1 (de)	2003-04-15
ZA9896B (en)	1998-10-14
AR010873A1 (es)	2000-07-12
CN1249745A (zh)	2000-04-05
ID23168A (id)	2000-03-23
JP2001508067A (ja)	2001-06-19
AU5912798A (en)	1998-08-03
ES2196534T3 (es)	2003-12-16
EA199900630A1 (ru)	2000-02-28
DE69812602T2 (de)	2004-02-19
IL130760A0 (en)	2001-01-28
NO993350L (no)	1999-09-06
NZ336560A (en)	2000-11-24
TR199901575T2 (xx)	1999-11-22
CO4920232A1 (es)	2000-05-29
DZ2395A1 (fr)	2003-06-04
BG103548A (en)	2000-11-30
PE44799A1 (es)	1999-06-10
WO1998030542A1 (en)	1998-07-16
PL334499A1 (en)	2000-02-28
EP0977735A1 (en)	2000-02-09
SK92799A3 (en)	1999-12-10
KR20000069941A (ko)	2000-11-25
US6069158A (en)	2000-05-30
MA26462A1 (fr)	2004-12-20
AU729641B2 (en)	2001-02-08

Publication	Publication Date	Title
OA11076A (en)	2003-03-13	Vitronectin receptor antagonists
AU733417B2 (en)	2001-05-17	Vitronectin receptor antagonists
JP2000502708A (ja)	2000-03-07	ビトロネクチン受容体拮抗物質
HU226056B1 (en)	2008-04-28	Acetic acid derivatives with dibenzo[a,d]cycloheptene and dibenz[b,e]azepine skeleton, process for their preparation and pharmaceutical compositions containing them
WO1999005107A1 (en)	1999-02-04	Vitronectin receptor antagonist
AU738433B2 (en)	2001-09-20	Vitronectin receptor antagonists
CA2304000A1 (en)	1999-04-01	Vitronectin receptor antagonist
EP1146874B1 (en)	2004-09-22	Vitronectin receptor antagonist
US20020019387A1 (en)	2002-02-14	Vitronectin receptor antagonist
CZ241599A3 (cs)	2000-01-12	Antagonista vitronektinového receptorů
US6576643B2 (en)	2003-06-10	Vitronectin receptor antagonists
CZ2000979A3 (cs)	2000-11-15	Antagonista vitronektinového receptoru
MXPA01005547A (es)	2001-12-04	Antagonista del receptor de vitronectina